Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymphocyte

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    732 result(s) found for: Lymphocyte. Displaying page 2 of 37.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-000889-22 Sponsor Protocol Number: ICKTI08TX01 Start Date*: 2008-11-11
    Sponsor Name:Imperial College Healthcare NHS Trust
    Full Title: A randomised controlled comparison of standard release Tacrolimus vs extended-release Tacrolimus as baseline maintenance monotherapy for kidney transplantation after induction with Campath 1-H.
    Medical condition: Prevention of allograft rejection after renal transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023439 Kidney transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002910-39 Sponsor Protocol Number: NC19453 Start Date*: 2006-07-31
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 over a 24-week period in Patients with CHD or a CHD Risk Equivalent
    Medical condition: CHD or CHD Risk Equivalent
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000741-19 Sponsor Protocol Number: Fl SC ale (Full-Scale) Start Date*: 2007-07-04
    Sponsor Name:UHL NHS Trust
    Full Title: A phase I study of subcutaneous alemtuzumab in combination with oral fludarabine in previously untreated patients with chronic lymphocytic leukaemia.
    Medical condition: Chronic Lymphocytic Leukaemia (CLL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006713-25 Sponsor Protocol Number: ASSENTE Start Date*: 2008-09-23
    Sponsor Name:OSPEDALE MAGGIORE DI MILANO (IRCCS)
    Full Title: A SINGLE-ARM PILOT STUDY WITH LOW-DOSE RITUXIMAB PLUS STANDARD ORAL PREDNISONE IN IDIOPATHIC AUTOIMMUNE HEMOLYTIC ANEMIA
    Medical condition: ANEMIE EMOLITICHE AUTOIMMUNI IDIOPATICHE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003685-33 Sponsor Protocol Number: HLS01/2006 Start Date*: 2006-09-27
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO A.O. DI RILIEVO NAZIONALE
    Full Title: Study of viro-immunological dynamics and T-lymphocyte homeostasis in peripheral blood in the pathogenesisof HIV infection and in the response to antiretroviral therapy.
    Medical condition: Treatment of HIV-1 infection in INRs patients compared to classical HAART.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003581 Asymptomatic HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004677-18 Sponsor Protocol Number: BRD07/11-U Start Date*: 2008-10-03
    Sponsor Name:CHU de Nantes
    Full Title: Etude prospective monocentrique: Analyse et corrélation de la réaction immunologique locale et systémique induite par des instillations endovésicales de BCG (Bacille de Calmette et Guérin) dans le ...
    Medical condition: Patients présentant un cancer superficiel de la vessie.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004849-26 Sponsor Protocol Number: Parachute04 Start Date*: 2015-02-05
    Sponsor Name:UMC Utrecht
    Full Title: PARACHUTE-trial Prospective Analysis of an individualized dosing Regimen of ATG (Thymoglobulin) in Children Undergoing HCT: redUcing Toxicity and improving Efficacy – a single arm phase II study
    Medical condition: Leukemia and immunedeficiency syndromes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    20.1 100000004864 10024329 Leukemia LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-004727-36 Sponsor Protocol Number: NR 8230-3/2004 Start Date*: 2005-02-10
    Sponsor Name:Charles University, 3rd Faculty of Medicine
    Full Title: Influence of low-dose i.v. growth hormone treatment together with glutamine supplementation in late-phase critically ill patient after multiple injury. A pilot study.
    Medical condition: Prolonged phase of critical illness after severe multiple trauma
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001028-16 Sponsor Protocol Number: EARLY-DEX Start Date*: 2021-05-21
    Sponsor Name:Fundación para la Investigación e Innovación Biomédica (FIIB) del Hospital Universitario Infanta Leonor y Hospital Unive
    Full Title: DEXamethasone EARLY administration in hospitalized patients with Covid-19 pneumonia and high risk of developing acute respiratory distress syndrome
    Medical condition: Hospitalized patients with Covid-19 pneumonia who do not require oxygen therapy on admission associated with at least two of the three following factors related with severe Covid-19: lactate dehydr...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002497-27 Sponsor Protocol Number: KFJ-2020-01_IMUNOR Start Date*: 2020-10-27
    Sponsor Name:Thomayerova nemocnice
    Full Title: A randomized, open-label, phase IV monocentric study evaluating the clinical effect of oral immunomodulatory therapy with IMUNOR® in patients with moderate COVID-19 disease
    Medical condition: Patients with COVID -19 disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003056-36 Sponsor Protocol Number: CBAF312A2304 Start Date*: 2012-10-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary pro...
    Medical condition: Secondary progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) IE (Completed) DE (Prematurely Ended) CZ (Completed) SK (Completed) NL (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Completed) SE (Completed) PT (Prematurely Ended) IT (Prematurely Ended) LV (Completed) GR (Completed) LT (Completed) EE (Completed) BE (Prematurely Ended) PL (Completed) BG (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-002565-20 Sponsor Protocol Number: MOR-ddi-01-2004 Start Date*: 2004-11-22
    Sponsor Name:Asociación para el estudio de enfermedades infecciosas
    Full Title: Food effect on antiviral activity of videx enteric-coated capsules
    Medical condition: Asymptomatic HIV Infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003128-30 Sponsor Protocol Number: Uni-Koeln-1776 Start Date*: 2016-05-19
    Sponsor Name:University of Cologne
    Full Title: Phase II trial of the Btk-inhibitor Ibrutinib in patients with relapsed nodular lymphocyte-predominant Hodgkin Lymphoma (NLPHL)
    Medical condition: relapsed lymphocyte-predominant Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000082-41 Sponsor Protocol Number: 2021-0486 Start Date*: 2022-03-31
    Sponsor Name:Fundación para la Investigación en Urología
    Full Title: Impact of pitavastatin use in prostate cancer patients treated with new generation androgen therapy: multicenter clinical trial
    Medical condition: We propose a multicenter, prospective, randomized, single-blind clinical trial, without conflict of interest, to determine the clinical benefit of statins (Pitavastatin 2 mg) in prostate cancer pa...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022677-34 Sponsor Protocol Number: EMR200109-619 Start Date*: 2011-09-07
    Sponsor Name:Dekan des Fachbereichs Humanmedizin
    Full Title: Influence of high dose vitamin D substitution on humoral immunity and lymphocyte function in patients with type 1 diabetes mellitus or Addison´s disease (ViDDA1)
    Medical condition: Type 1 diabetes mellitus or Addison´s disease (ViDDA1)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10001353 Adrenal gland disorders HLGT
    14.1 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001366-42 Sponsor Protocol Number: BGB-3111-305 Start Date*: 2018-11-07
    Sponsor Name:BeiGene, Ltd.
    Full Title: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10041152 Small lymphocytic lymphoma, consistent with CLL (Working Formulation) LLT
    20.1 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) BE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) SE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005178-43 Sponsor Protocol Number: OMB115991 Start Date*: 2012-02-08
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients with Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)
    Medical condition: Untreated or Relapsed Chronic Lymphocytic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10008968 Chronic lymphocytic leukaemia stage A(0) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Prematurely Ended) BE (Completed) ES (Completed) PL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000647-30 Sponsor Protocol Number: EFC16645 Start Date*: 2020-08-27
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis
    Medical condition: Non-relapsing Secondary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) FR (Completed) DE (Restarted) GB (GB - no longer in EU/EEA) CZ (Completed) NO (Completed) FI (Completed) DK (Completed) BE (Completed) LT (Completed) AT (Completed) GR (Completed) NL (Completed) PT (Completed) PL (Completed) HU (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001799-39 Sponsor Protocol Number: CBAF312X2206 Start Date*: 2013-09-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double blind, randomized, placebo-controlled study to evaluate, safety, tolerability, efficacy and preliminary dose-response of BAF312 in patients with active dermatomyositis.
    Medical condition: Active dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005035-19 Sponsor Protocol Number: A3921024 Start Date*: 2007-04-17
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB (CP-690,550) FOR TREATMENT OF RHEUMATOID ARTHRITIS
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) AT (Completed) SE (Completed) IT (Completed) HU (Completed) CZ (Completed) GR (Completed) DE (Completed) SK (Completed) GB (Completed) BG (Completed) FI (Completed) DK (Completed) IE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 04:33:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA